IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for FDC Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.
Revenue projections:
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 0.00000 |
| debtToEquity | 0.85200 |
| earningsGrowth | -0.23700 |
| revenueGrowth | 0.00100 |
| grossMargins | 0.66139 |
| operatingMargins | 0.08069 |
| trailingEps | 13.32000 |
| forwardEps | 23.30000 |
FDC Limited's low earnings and revenue growth point to a possible reduction in profits. This trend suggests that the company may face difficulties in maintaining its profitability and could be a cause for concern among investors.
FDC Limited's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
FDC's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that FDC is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.
Recommendation changes over time:
Analysts' recent buy bias toward FDC suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see FDC as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape